Biogen: Second Time’s A Charm, Likely Approval Of Lecanemab (NASDAQ:BIIB)
ipopba Biogen (NASDAQ:BIIB) has recently surged again on positive results from their Alzheimer’s drug portfolio. Investors are more tepid on the drug benefits this time after the approved aducanumab drug failed to gain market traction […]
